Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2011-02-16 Regulatory Filings
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Phylogica Announces Successful Collaboration with Roche 2 pages 86.7KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful completion of initial research objectives in a collaboration between Phylogica Ltd and Roche. It discusses scientific progress and future plans but does not contain financial statements, regulatory filings, voting results, or management changes. The document is relatively short (4052 characters) and serves as a corporate announcement about a collaboration milestone rather than a financial or regulatory report. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is best classified as a general regulatory announcement or corporate update that does not fit other specific categories, which corresponds to Regulatory Filings (RNS).
2011-02-16 English
Shareholder Update February 2011 2 pages 801.9KB
Regulatory Filings Classification · 70% confidence The document is a detailed newsletter from Phylogica dated February 2011, addressed to shareholders. It discusses collaborations with pharmaceutical companies, licensing payments, anticipated collaborations, and the company's business model and prospects. There are no financial statements, regulatory certifications, or formal report structures typical of annual or interim reports. The content is informational and promotional, aimed at shareholders and investors to update them on company activities and outlook. It does not fit categories like Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or Regulatory Filings (RNS). It is not a formal investor presentation (IP) either, as it is more narrative and less structured as a presentation. The document resembles a shareholder newsletter or an investor update letter, which is not explicitly listed in the categories. The closest fitting category is Annual Report (10-K) if it were a formal report, but this is not the case. Given the options, the best fit is Regulatory Filings (RNS) as a fallback for miscellaneous shareholder communications that do not fit other categories. Confidence is moderate due to the document's nature as a shareholder update but not a formal report.
2011-02-06 English
Change in substantial holding 2 pages 161.8KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of Change of Interests of Substantial Holder under the Corporations Act 2001. It details changes in voting power and relevant interests of a substantial shareholder in Phylogica Limited. This type of filing is a notification of changes in significant share ownership levels, which corresponds to a Major Shareholding Notification. The document is not a financial report, earnings release, or management report, but a regulatory disclosure about shareholding changes.
2011-02-02 English
Change of Substantial Holding - Correction 2 pages 164.0KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of Change of Interests of Substantial Holder under the Corporations Act 2001. It details changes in voting power and relevant interests of a substantial shareholder in Phylogica Limited. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document is not a financial report, management announcement, or other types of filings. Therefore, the correct classification is MRQ.
2011-02-02 English
Appendix 4C - quarterly 7 pages 63.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Report 31 December 2010' and contains detailed financial information including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, payments to directors, reconciliation of cash, and compliance statements. The report covers a quarter ended 31 December 2010, indicating it is a quarterly financial report. The length of the document (11,202 characters) and the presence of substantive financial data and analysis confirm it is a full financial report rather than a brief announcement or certification. The document matches the characteristics of an Interim / Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. Therefore, the correct classification is IR (Interim / Quarterly Report). Q4 2010
2011-01-27 English
Phylogica Named as One of Bioshares `Top 10 Picks` for 2011 2 pages 80.7KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Phylogica Ltd has been named as one of Bioshares 'Top 10 Picks' for 2011. It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no detailed report content. The document is short (4061 characters) and serves as an announcement of an external recognition or accolade rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. It is not a report publication announcement either, as it does not mention any report being published or attached. The content is best classified as a general Regulatory Filing (RNS) since it is a public announcement related to the company but does not fit any other specific category.
2011-01-24 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.